KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.98

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial.

Qingchun Diao, Ruiling Jia, Min Li, Peng Zhao, Fang Lu, Qin Zhang, Chunzhu Ning, Juan Long, Jiajia Li, Yan Huang, Yuyi Wang

J Dermatolog Treat 36(1) 2591478

PMID41288059
PMCID-
DOI10.1080/09546634.2025.2591478
发表日期2025-11-25
入排依据:未发现恶性肿瘤人群证据。
入排复审未纳入:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD). OBJECTIVE: This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments. METHODS: This was a post-hoc analysis of a phase III clinical trial of Ivarmacitinib in moderate-to-severe AD (NCT04875169). Subgroup analysis by with (N = 132) or without (N = 204) previous systemic treatments (systemic corticosteroids, biologics, or other immunomodulators) was performed. RESULTS: In patients with previous systemic treatments, Ivarmacitinib 8 mg (n = 34) and 4 mg (n = 53) exhibited higher Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI)-75, EASI-90, and Worst Itch Numeric Rating Scale (WI-NRS) 4 response rates, and a greater reduction in Dermatology Life Quality Index (DLQI) score compared with placebo (n = 45) at most timepoints from W4 to W16. In patients without previous systemic treatments, these outcomes were notably increased in Ivarmacitinib 8 mg (n = 78) and 4 mg (n = 60) versus placebo (n = 66) throughout W4 to W16. The adverse events were generally comparable between Ivarmacitinib and placebo groups, regardless of previous systemic treatments. CONCLUSION: Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。